Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.55 |
| ▸ | S1PR2 known ✓ | O95136 | 5/20 | 0.47 |
| ▸ | S1PR1 known ✓ | P21453 | 5/20 | 0.47 |
| ▸ | S1PR3 known ✓ | Q99500 | 5/20 | 0.47 |
| ▸ | S1PR4 known ✓ | O95977 | 4/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LAP3 | P28838 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8706640 | 1.00 | OPRM1 (0.55) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| Hydrochloric Acid SCHEMBL11832911 | 0.97 | PLA2G1B (0.56) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| Hydrochloric Acid SCHEMBL28443603 | 0.97 | PLA2G1B (0.56) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| Hydrochloric Acid SCHEMBL27755493 | 0.97 | PLA2G1B (0.56) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| Hydrochloric Acid SCHEMBL233603 | 0.97 | PLA2G1B (0.56) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| Hydrochloric Acid SCHEMBL10417683 | 0.97 | PLA2G1B (0.56) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| Hydrochloric Acid SCHEMBL11783993 | 0.97 | PLA2G1B (0.56) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| Hydrochloric Acid SCHEMBL10531869 | 0.97 | PLA2G1B (0.56) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| Hydrochloric Acid SCHEMBL1397744 | 0.97 | PLA2G1B (0.56) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 | |
| Hydrochloric Acid SCHEMBL27515102 | 0.97 | PLA2G1B (0.56) | OPRM1PLA2G1BPLA2G2AS1PR2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1048492-C | Quinuclidine derivatives and process for preparation thereof | PFIZER (US) | 2000-01-19 | — | — | CN | claimed |
| US-5807867-A | Quinuclidine derivatives | PFIZER INC. (US) | 1998-09-15 | — | — | US | claimed |
| EP-0587723-A1 | QUINUCLIDINE DERIVATIVES. | PFIZER (US) | 1994-03-23 | — | — | EP | claimed |
| CN-1067428-A | QUINUCLIDINE DERIVATIVES | PFIZER (US) | 1992-12-30 | — | — | CN | claimed |
| WO-1992021677-A1 | bibNUCLIDINE DERIVATIVES | PFIZER INC. (US) | 1992-12-10 | — | — | WO | claimed |
| CN-117263932-A | Method for reducing residual solvent in palonosetron hydrochloride | 药源药物化学（上海）有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117263931-A | Method for preparing palonosetron hydrochloride | 药源药物化学（上海）有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-114341124-A | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-112805280-A | Heteroaryl compounds for the treatment of huntington's disease | PTC医疗公司 | 2021-05-14 | — | — | CN | disclosed |
| CN-107652310-A | The cephem compounds of 2 substitutions | 葛兰素集团有限公司 | 2018-02-02 | — | — | CN | disclosed |
| CN-104884460-B | 2-substituted Cephem compounds | 葛兰素集团有限公司 | 2017-11-03 | — | — | CN | disclosed |
| CN-104884460-A | 2-substituted Cephem compounds | GLAXO GROUP LTD | 2015-09-02 | — | — | CN | disclosed |
| CN-1423651-A | Novel use and novel N-azabicyclo-amide derivatives | ASTRAZENECA AB (SE) | 2003-06-11 | — | — | CN | disclosed |
| WO-2003042210-A1 | AZABICYCLIC-PHENYL-FUSED-HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALPHA7 NACHR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003029252-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
| CN-1400973-A | Novel biarylcarboxamides | ASTRAZENECA AB (SE) | 2003-03-05 | — | — | CN | disclosed |
| CN-1353702-A | Adamantane derivative | ASTRAZENECA AB (SE) | 2002-06-12 | — | — | CN | disclosed |
| CN-1048727-C | Process for preparation of 2-(1-azabicyclo(2,2,2)oct-3-yl)-2,4,5,6-tetrahydro-1H-benz (DE)isoquinolin-1-1one and intermediate product | HOFFMANN LA ROCHE (CH) | 2000-01-26 | — | — | CN | disclosed |
| US-5721255-A | Substituted benzylamino nitrogen containing non-aromatic heterocycles | PFIZER INC. (US) | 1998-02-24 | — | — | US | disclosed |
| CN-1152313-A | Process for preparing 2- (1-azabicyclo [2, 2, 2] oct-3-yl) -2, 4, 5, 6-tetrahydro-1H-benzo [ DE ] isoquinolin-1-one and intermediates thereof | HOFFMANN LA ROCHE (CH) | 1997-06-18 | — | — | CN | disclosed |